Comparative Pharmacology
Head-to-head clinical analysis: FETROJA versus ULTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FETROJA versus ULTRACEF.
FETROJA vs ULTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefiderocol is a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, and is stable against a broad range of beta-lactamases, including carbapenemases, due to its ability to penetrate the outer membrane via the bacterial iron transport system.
Cefadroxil, a first-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis. It is bactericidal against susceptible organisms.
1 gram intravenously over 3 hours every 8 hours in patients 18 years and older with creatinine clearance ≥ 60 mL/min.
250 mg orally every 6 hours or 500 mg orally every 12 hours for uncomplicated urinary tract infections; 1 g orally every 12 hours for complicated urinary tract infections.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours; prolonged in renal impairment (e.g., up to 5-6 hours in severe renal impairment), requiring dose adjustment
0.5–1.2 hours in normal renal function; prolonged to 2–4 hours in severe renal impairment (CrCl <10 mL/min).
Renal: approximately 65-70% of the dose excreted unchanged in urine; biliary/fecal: minimal (<1%)
Approximately 90% of an oral dose is excreted unchanged in urine via glomerular filtration and tubular secretion; less than 1% is excreted in feces via biliary elimination.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic